Literature DB >> 28250699

Rolapitant (Varubi): A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Tamara Goldberg, Brooke Fidler, Stephanie Cardinale.   

Abstract

Rolapitant (Varubi) for the prevention of chemotherapy-induced nausea and vomiting.

Entities:  

Year:  2017        PMID： 28250699      PMCID： PMC5312632     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  6 in total

1.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.

Authors:  Lee S Schwartzberg; Manuel R Modiano; Bernardo L Rapoport; Martin R Chasen; Cesare Gridelli; Laszlo Urban; Allen Poma; Sujata Arora; Rudolph M Navari; Ian D Schnadig
Journal:  Lancet Oncol       Date:  2015-08-10       Impact factor: 41.316

2.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.

Authors:  Bernardo L Rapoport; Martin R Chasen; Cesare Gridelli; Laszlo Urban; Manuel R Modiano; Ian D Schnadig; Allen Poma; Sujata Arora; Vikram Kansra; Lee S Schwartzberg; Rudolph M Navari
Journal:  Lancet Oncol       Date:  2015-08-10       Impact factor: 41.316

3.  Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting.

Authors:  Fahad Aziz
Journal:  Ann Palliat Med       Date:  2012-07

Review 4.  Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.

Authors:  K Jordan; F Jahn; M Aapro
Journal:  Ann Oncol       Date:  2015-03-09       Impact factor: 32.976

Review 5.  Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.

Authors:  Rudolph M Navari; Matti Aapro
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

Review 6.  Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.

Authors:  Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739
  6 in total
  1 in total

Review 1.  Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.

Authors:  Marilina García-Aranda; Teresa Téllez; Lauraine McKenna; Maximino Redondo
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.